Cardiff Oncology

Company snapshot

Cardiff Oncology maintains 58 tracked programs across Colorectal Cancer, Psoriatic Arthritis, Rheumatoid Arthritis, Acute Myeloid Leukaemia, Type 1 Diabetes, Pancreatic Cancer, Bladder Cancer, Postoperative; Dysfunction Following Cardiac Surgery, Tuberous Sclerosis, Blood cancer, Anal cancer, Human papillomavirus (HPV)-positive oropharyngeal cancer, Platelet Dysfunction Due to Aspirin. Momentum sc

• 58 active pipeline program(s) linked via ClinicalTrials.gov.
• 69 US patent(s) indexed to this assignee profile.
• 58 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cardiff Oncology. Not investment advice.

• trial_data Jun 8, 2026

  Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts

• Peer + 0 momentum

  MEREO BIOPHARMA GROUP

  TA overlap score 29.4

• Peer + 0 momentum

  Samsung Bioepis

  TA overlap score 24.8

Recent activity

Latest pipeline, patent, and corporate events for Cardiff Oncology.

1. Jun 8, 2026 Clinical update

   SPON - 1751-19 — Phase 2

2. Jun 8, 2026 Clinical update

   CISPLATIN, CARBOPLATIN — Phase 3

3. Jun 8, 2026 Clinical update

   Tyenne 162 mg solution for injection in pre-filled pen — Phase 2

4. Jun 8, 2026 Clinical update

   Tyenne 162 mg solution for injection in pre-filled pen — Phase 2

5. Jun 8, 2026 Clinical update

   KEYTRUDA 25 mg/mL concentrate for solution for infusion — Phase 2

View all clinical trial activity →

• What is Cardiff Oncology?

  Cardiff Oncology is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker CRDF. Primary therapeutic focus areas include Colorectal Cancer, Psoriatic Arthritis, Rheumatoid Arthritis, Acute Myeloid Leukaemia, Type 1 Diabetes, Pancreatic Cancer. Nova

• Is Cardiff Oncology publicly traded?

  Yes. Cardiff Oncology is listed with ticker CRDF on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Cardiff Oncology develop or market?

  We link 62 drug profile(s) where Cardiff Oncology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cardiff-oncology#company-drugs.

• What are the latest developments for Cardiff Oncology?

  In the last 12 months our linked public records show 58 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Cardiff Oncology focus on?

  Cardiff Oncology focuses on Colorectal Cancer, Psoriatic Arthritis, Rheumatoid Arthritis, Acute Myeloid Leukaemia based on our analysis of their pipeline programs and drug development activities.